<DOC>
	<DOCNO>NCT01452698</DOCNO>
	<brief_summary>The purpose study determine efficacy TAK-438 , daily ( QD ) , compare lansoprazole patient erosive esophagitis Grade A D define LA classification grade system .</brief_summary>
	<brief_title>Efficacy TAK-438 Compared AG-1749 ( Lansoprazole ) Treatment Erosive Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>1 . At Visit 1 ( start observation period ) , participant must endoscopically confirm erosive esophagitis Grade A D , define LA classification grade system , target number participant clearly Grade C D 30 % ( 120 participant ) total participant . 2 . Outpatient ( include inpatient examination ) 1 . Participants esophagusrelated complication ( eosinophilic esophagitis , esophageal varix , scleroderma , viral fungal infection , esophageal stenosis , etc . ) , history radiotherapy cryotherapy esophagus , caustic physiochemical trauma ( esophageal sclerotherapy , etc. ) . However , participant Schatzki 's ring ( mucosal tissue ring around inferior esophageal sphincter ) Barrett 's esophagus allow include . 2 . Participants receive surgery treatment affect gastroesophageal reflux ( cardioplasty , dilation esophageal stenosis [ exclude Schatzki 's ring ] , etc . ) , history surgery stomach duodenum ( exclude removal benign polyp endoscopy ) 3 . Participants acute upper gastrointestinal bleeding , gastric duodenal ulcer ( mucosal defect white coating ) within 30 day prior Visit 1 ( start observation period ) . However , participant gastric duodenal erosion allow include . 4 . Participants previous current history ZollingerEllison syndrome , gastric acid hypersecretion disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>